The neuroprotective properties of Sigma1R ligands and IRE1α inhibitors presented in a number of studies are consistent with the effects of attenuating gene expression of proteins providing IRE1α signaling in models of AD [213], PD [440,441], ALS [98,442,443], and HT [103]. The gene discussed is ERN1; the disease is Parkinson disease.